💊 Fármacos A-Z 🧬 Dianas 🛠 Herramientas 📚 Guías
Todos los fármacos Clases de fármacos Áreas terapéuticas Efectos Secundarios
Guías Glosario Línea de tiempo
Comparaciones Recorridos de fármacos Familias farmacológicas
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Dimethyl Fumarate

CHEMBL2107333 Phase 4 Aprobado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
144.1 g/mol
LogP
0.7
Phase
4

An oral medication used to treat relapsing forms of multiple sclerosis and moderate-to-severe psoriasis by activating the Nrf2 pathway, which reduces oxidative stress and has anti-inflammatory effects. In multiple sclerosis, it reduces the frequency of relapses and slows disability progression. Flushing and gastrointestinal side effects are common early in treatment, and patients require monitoring of lymphocyte counts.

Peso molecular

144,1200 g/mol

LogP

0,70

TPSA

52,60 Ų

Regla de cinco de Lipinski

Cumple

Áreas terapéuticas

Artritis reumatoide Degeneración macular relacionada con la edad Diabetes tipo 2 Enfermedad cardiovascular Enfermedad de Alzheimer Esclerosis múltiple Hipertensión Ictus Leucemia Linfoma Lupus eritematoso sistémico Melanoma Psoriasis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COC(=O)/C=C/C(=O)OC

                

                

                
                

                    
InChI

                    
InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+

                

                

                

                    
                    

                        
Molecular Formula

                        
C6H8O4

                    

                    
                    

                        
HBD / HBA

                        
- / 4

                    

                    
                    

                        
Enlaces Rotables

                        
4

                    

                    
                    
                    

                        
Átomos Pesados

                        
10

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Preguntas frecuentes

                

                    
                    

                        
                        

                            
An oral medication used to treat relapsing forms of multiple sclerosis and moderate-to-severe psoriasis by activating the Nrf2 pathway, which reduces oxidative stress and has anti-inflammatory effects. In multiple sclerosis, it reduces the frequency of relapses and slows disability progression. Flushing and gastrointestinal side effects are common early in treatment, and patients require monitoring of lymphocyte counts.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Dimethyl Fumarate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL2107333.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 637568.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Aviso médico

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.